Brief: Equillium Presents Interim Safety Data And Reduction In Proteinuria For Lupus Patients Treated With Itolizumab At ACR Annual Meeting

Equillium

02/11/2021 12:12

Nov 2 (Reuters) - Equillium Inc  EQ.O :
    * EQUILLIUM ANNOUNCES INTERIM SAFETY DATA AND REDUCTION IN
PROTEINURIA FOR LUPUS PATIENTS TREATED WITH ITOLIZUMAB IN
EQUALISE STUDY PRESENTED AT ACR ANNUAL MEETING
    * EQUILLIUM INC - ITOLIZUMAB WAS WELL TOLERATED AT DOSES
RANGING
FROM 0.4 TO 2.4 MG/KG
    * EQUILLIUM - SUBGROUP ANALYSES OF LUPUS PATIENTS WITH
ELEVATED
BASELINE PROTEINURIA & ALBUMINURIA SHOWS REDUCTION OF 42% & 54%,
RESPECTIVELY, BY DAY 57

Source text for Eikon:  ID:nBw31jrvba 
Further company coverage:  EQ.O 

 ((Reuters.Briefs@thomsonreuters.com;;))